|
PRODUCT PIPELINE
Icagen is conducting clinical and preclinical studies in its core focus areas, which include the following:
- Epilepsy and Neuropathic Pain
ICA-105665 recently completed Phase I clinical studies. ICA-105665 is a novel
opener of the KCNQ ion channel which in preclinical studies has
demonstrated a broad spectrum of activity in models of epilepsy. In addition,
ICA-105665 has also demonstrated activity in certain models of
neuropathic pain.
Senicapoc, formerly known as ICA-17043 is currently in Phase II clinical
studies. In previous clinical studies senicapoc has demonstrated a favorable
safety and tolerability profile.
Icagen has a broad research effort directed at novel ion channel targets for
pain control. In August, 2007, Icagen entered into a collaboration with
Pfizer for the discovery and development of novel pharmaceuticals directed
against three sodium channel targets. In addition, Icagen is pursuing research
directed at multiple calcium channels as well as other novel ion channel
targets in its pain control program.
Icagen has a broad research effort directed at novel ion channel targets for
inflammatory disorders. As a result, Icagen has identified several ion channel
targets that are expressed at high levels in some immune system cells and
that may play an important role in modulating the inflammatory response.
Icagen has discovered compounds that are active in vitro against some of
these targets, leading to decreases in calcium entry into immune system
cells, decreases in immune system cell proliferation, decreases in immune
system cell migration into tissues and other measures of inflammatory
responses. Icagen has also demonstrated effects of our compounds in
animal models of inflammatory diseases.
In addition to the areas noted above, Icagen is continuing to explore the human ion channel genome, for which it has completed the cloning of all human ion channel genes, to identify new therapeutic opportunities.
|
